Sonnest, Inc., a Philadelphia, PA-based pre-clinical healthcare company, raised more than $4M in a Series A financing.
The round was led by the Swan Impact Network, Robin Hood Ventures and the Texas Halo Fund and included a number of doctors, and prominent angel investors.
The company intends to use the funds to advance Electrast™ into the clinic, confirm the safety profile of the drug and generate proof-of-principle ultrasound images in human patients similar to the videos created to date in pigs and dogs.
Led by Peter Boyd, CEO, Sonnest is developing Electrast™, a voltage-activated ultrasound imaging drug for myocardial perfusion imaging. Electrast™ circulates through the body in the inactive state (dark on ultrasound) and is selectively activated (turned on) in the myocardium. With it doctors will be able to evaluate perfusion of the heart quickly at the point of care without exposure to ionizing radiation or toxic dyes.